| Bias | Author's judgement | Support for judgement |
| Randomization |
Some concerns |
Randomization was accomplished by using a random table that was generated in SAS software at 1:1. Each enrolled subject (meeting all the inclusion criteria and not meeting any of the exclusion criteria) was given a number, randomly assigned to the FNC group and control group according to a predetermined random table (Figure S1, Supporting Information), and received treatment according to the corresponding treatment regimen. Comment: It is unclear whether the allocation was concealed. |
| Deviations from intervention |
Some concerns |
Comment: Unblinded study.
No patient cross-over. No information on co-intervention administration of antivirals, biologics, glucorticoids and anticoagulants were reported. Trialists used ITT analyses. |
| Missing outcome data |
Low |
Comment: 10 randomized/ 10 analyzed. ITT analysis Risk assessed to be low for the outcomes: Mortality. Viral negative conversion events. Adverse events. Serious adverse events. |
| Measurement of the outcome |
Some concerns |
Comment: Open label trial. Mortality, Viral Negative Conversion events and Serious adverse events are observer-reported outcomes not involving judgement. Risk assessed to be low for outcomes: Mortality, Viral Negative Conversion events and Serious adverse events Adverse events reflects a decision made by the intervention provider where the assessment could possibly be influenced by knowledge of the intervention assignment however we did not consider this likely in the context of a pandemic. Risk assessed to be some concerns for outcomes: Adverse events |
| Selection of the reported results |
Some concerns |
Comment: There is no protocol or statistical plan available in English.(Available in Chinese) Risk assessed to be some concerns for the outcomes: Mortality. Viral negative conversion events. Adverse events. Serious adverse events. |
| Overall risk of bias |
Some concerns |